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Background—Low heart rate variability (HRV) is associated with a higher risk of death in patients with heart disease and
in elderly subjects and with a higher incidence of coronary heart disease (CHD) in the general population.
Methods and Results—We studied the predictive value of HRV for CHD and death from several causes in a population
study of 14 672 men and women without CHD, aged 45 to 65, by using the case-cohort design. At baseline, in 1987
to 1989, 2-minute rhythm strips were recorded. Time-domain measures of HRV were determined in a random sample
of 900 subjects, for all subjects with incident CHD (395 subjects), and for all deaths (443 subjects) that occurred through
1993. Relative rates of incident CHD and cause-specific death in tertiles of HRV were computed with Poisson regression
for the case-cohort design. Subjects with low HRV had an adverse cardiovascular risk profile and an elevated risk of
incident CHD and death. The increased risk of death could not be attributed to a specific cause and could not be
explained by other risk factors.
Conclusions—Low HRV was associated with increased risk of CHD and death from several causes. It is hypothesized that
low HRV is a marker of less favorable health. (Circulation. 2000;102:1239-1244.)
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The heart rate of healthy persons displays beat-to-beatvariations that result from fluctuations in autonomic
nervous system activity at the sinus node. Heart rate variabil-
ity (HRV) decreases under situations of stress, either emo-
tional or physical, whereas it increases with rest. Therefore,
HRV is considered a noninvasive marker of autonomic
nervous system function.1,2 The lack of HRV has long been
used for the diagnosis of diabetic neuropathy. In more recent
years, low HRV has been shown to have prognostic value in
patients with myocardial infarction.3 Also, in the general
population, low HRV is associated with death4,5 and with the
risk of cardiac events.6,7 Because low HRV has been reported
in patients with diabetes, hypertensive cardiac hypertrophy,
and atherosclerosis,1,8,9 prevalent disease may account for
these findings. It is questioned whether, in the general
population, low HRV is a consequence of disease or an
indicator of an underlying mechanism for future disease;
therefore, we studied HRV in relation to total and CHD
mortality risk in the Atherosclerosis Risk In Communities
(ARIC) Study.
Methods
Study Population and Baseline Measurements
The ARIC Study follows a cohort of 15 792 middle-aged men and
women.10 During 1987 to 1989, population samples were drawn
from the 45- to 64-year-old inhabitants of Forsyth County, NC;
Jackson, Miss; suburban Minneapolis, Minn; and Washington
County, Md; and they were invited for a home interview and a
clinical examination.
In the home interview, questions were asked about health behav-
iors, sociodemographics, and disease history. The clinical examina-
tion included an ECG recording. After a 5- to 10-minute rest period,
during which electrodes were placed, each subject had a standard
12-lead ECG and a 2-minute rhythm strip recorded. Plasma total
cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride
levels were determined with standard methodology. Serum insulin
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was measured with a radioimmunoassay (125I Insulin Kit; Cambridge
Medical Diagnostics). Serum glucose was assessed with the hexoki-
nase method. Prevalent diabetes mellitus was defined as a fasting
glucose level of $140 mg/dL ($7.8 mmol/L), a nonfasting glucose
level of $200 mg/dL ($11.1 mmol/L), or a history of, or treatment
for, diabetes. Three seated blood pressure measurements were taken
on the right arm with a random-zero sphygmomanometer. The mean
of the last 2 measurements was used. Hypertension was defined as
systolic blood pressure of $140 mm Hg, diastolic blood pressure of
$90 mm Hg, or the use of antihypertensive agents. The ratio of waist
(umbilical level) and hip (maximum buttocks) circumferences was
calculated as a measure of fat distribution. The average carotid
intima-media thickness was assessed with a standardized B-mode
ultrasonic technique.11
Study Design and Methods of Follow-Up
Because it was not feasible to determine HRV for all participants, the
case-cohort design was applied, in which data are collected in the
complete cohort before disease occurs. At a later stage, the available
data are processed for the cases that occurred during follow-up and
in a random sample (including a number of future cases), which is
used to reflect the total cohort. This design provides estimates of
relative risks.12
For the present study, a random sample of 900 subjects was
selected in 1995 from the 14 672 subjects without prevalent coronary
heart disease (CHD) at baseline, combined with all incident CHD
cases and all deaths that occurred through 1993. Prevalent CHD was
defined as self-reported history of physician-diagnosed heart attack,
12-lead Minnesota Code evidence of prior myocardial infarction
(MI), prior cardiovascular surgery, or prior coronary angioplasty.
The method of follow-up has been described previously.13 Briefly,
interviewers contacted participants annually by telephone to identify
hospitalizations and deaths. For hospitalized patients with potential
acute CHD events, trained abstractors recorded the presenting signs
and symptoms, including chest pain, cardiac enzyme levels, and
related clinical information. As many as three 12-lead ECGs were
visually coded with the Minnesota Code, and waveform evolution
was evaluated with side-by-side comparisons.14 Out-of hospital
deaths were investigated by means of the death certificate, an
interview with the next-of-kin, and questionnaires completed by the
patients’ physicians. Coroner reports and autopsy reports, when
available, were used for validation.
CHD incidence was defined as definite or probable MI, cardiac
revascularization procedures (excluding thrombolytic therapy), or
definite CHD death. Cause-specific death was based on the under-
lying cause given on the death certificate: cardiovascular disease
(CVD) (ICD-9 codes 390 to 459) and cancer (ICD-9 codes 140 to
240). After the exclusion of subjects with missing data, the study
population consisted of 856 subjects in the random sample combined
with 395 incident CHD cases (29 were also part of the sample) and
443 deaths (21 were also part of the sample), of whom 140 died from
CVD and 209 died from cancer. Of the subjects who died from
cancer, 36 reported a history of cancer at baseline.
Data analysis
In 1995 to 1996, the duration of all normal sinus intervals (R-R
intervals) was measured at the University of Minnesota ECG Coding
Center by coders who were blinded with respect to disease occur-
rence during follow up. A digitizing tablet (Calcomp) and a personal
computer were used. Coders mounted the 2-minute rhythm strip on
the tablet and used the mouse to successively mark the top of all of
the R peaks. The X-Y coordinates were transmitted to the personal
computer, and the duration of the R-R interval was computed on the
basis of the difference between coordinates. To reduce measurement
error, the procedure was performed in duplicate, and the mean of the
2 measurements of each R-R interval was used for the analyses.
Abnormal beats were marked by the coders. The 2 intervals after a
single abnormal beat were excluded for analysis of HRV. Subjects
with .2 abnormal beats in the rhythm strip were excluded from the
analyses (36 in the random sample, 98 cases), because the presence
of multiple ventricular extrasystoles is known to be associated with
elevated mortality risk,15 and it is accompanied with higher HRV.
Four measures of HRV were determined: the standard deviation of
all R-R intervals (SDNN), the mean of absolute successive differ-
ences (rMSSD), the standard deviation of absolute differences
between successive intervals (SDSD), and the percentage of intervals
differing by .50 ms from the preceding interval (pNN50). In
addition, heart rate was calculated from the mean duration of R-R
intervals. HRV could not be determined for 4 subjects in the random
sample, and rhythm strips were missing for 3 subjects in the random
sample and for 23 cases.
The intercoder and intracoder variabilities were evaluated in a set
of 10 rhythm strips, which were measured 3 times by each coder.
HRV measures were used as the dependent variables. For the SDNN,
the between-subject variance was 310 ms2, the between-coder
variance was 0.04 ms2, and the intercoder variance was 3.24 ms2. The
correlation of all HRV measures between coders was .0.99.
Subjects were categorized a priori into 3 groups according to HRV
and heart rate. Categories were based on the tertile cut points of the
distribution of subjects in the random sample. The cut points were 23.9
and 35.4 ms for SDNN, 14.7 and 22.3 ms for rMSSD, 11.3 and 16.4 ms
for SDSD, 0.8% and 5.9% for pNN50, and 63 and 72 bpm for heart rate.
Relative incidence rates of CHD, total mortality, and cause-
specific mortality, in categories of all measures of HRV and of heart
rate, were computed with Poisson regression for the case-cohort
design.12 In line with previous work, the intermediate category was
taken as the reference.5 Subjects with a self-reported history of
cancer at baseline were excluded from the analyses of cancer risk.
Two models were used for the regression analyses. The first model
adjusted for age, sex, race group, and ARIC recruitment center; the
multivariable model also adjusted for variables that were associated with
HRV: current smoking, cigarette-years, triglycerides, HDL cholesterol,
diabetes, hypertension, body mass index, waist-to-hip ratio, and carotid
intima-media thickness. For cancer mortality, current smoking and
cigarette-years were added in the multivariable model.
Results
In the random sample of this population of middle-aged men
and women, mean6SD values were 34617 ms for SDNN,
22612 ms for rMSSD, 17612 ms for SDSD, 8612% for
pNN50, and 68610 bpm for heart rate. All measures of HRV
were significantly correlated, ranging from 0.70 between
pNN50 and SDNN to 0.95 between rMSSD and SDSD. The
correlations with heart rate were lower: 20.43 (SDNN and
pNN50) and 20.50 (SDSD and rMSSD).
In Table 1, population characteristics are shown in the
random sample in tertiles of SDNN. Age, male sex, heart rate,
body mass index, ratio of waist to hip circumferences, insulin
level, triglyceride level, HDL cholesterol level, blood pres-
sure, carotid intima-media thickness, and the prevalence of
hypertension and diabetes differed significantly for the HRV
categories, with subjects with low HRV in general having a
worse cardiovascular risk profile. Therefore, these variables
were considered possible confounding or mediating factors.
In the survival analysis (Table 2), low HRV and high heart
rate were associated with elevated risk of all end points. The
age-, sex-, race-, and field center–adjusted relative risks of
cardiovascular mortality in the lowest compared with the
intermediary tertile of SDNN was 2.10 (95% CI 1.21 to 3.64)
For rMSSD, SDSD, and pNN50, the relative risks of all end
points were higher than those observed for SDNN. The
relative risks were less favorable in the high than in the
intermediate tertile. A U shape was observed for cancer
mortality; the relative rates in the lowest and highest tertiles
of pNN50 were 1.95 (1.27 to 2.92) and 1.53 (0.97 to 2.41),
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respectively. Adjustment for possible confounders slightly
decreased the increased risks for the low SDNN and high
heart rate categories and increased the risks in the lowest
tertiles of rMSSD, SDSD, and pNN50 and in the high tertiles
of all measures of HRV.
Adjustment for insulin or glucose level in subjects without
diabetes did not affect the associations. Stratified analysis
was performed to evaluate possible confounding and interac-
tion. Stratification did not show appreciably different relative
risk estimates within subgroups of heart rate, age, sex, race,
hypertension, diabetes, smoking, or body mass index. Fur-
thermore, when analyses were restricted to subjects without
hypertension, diabetes, cancer, or symptomatic heart disease
at baseline, the associations with death remained virtually
unchanged (Table 3).
Discussion
In this population study, middle-aged men and women with
low HRV, as determined from a 2 minute-rhythm strip, had
an adverse cardiovascular risk profile and elevated risk of
death from all causes, including cancer, and of incident CHD.
The elevated risk could not be attributed to other risk factors.
Methodological Issues
In the present study, the case-cohort design was used. To
evaluate whether the cohort sample was a representative
sample, we compared mean values for cardiovascular risk
factors of the cohort sample versus those of the full cohort.
None of these values were significantly different, and they
never differed by .1%. It is therefore likely that the distri-
butions of measures of HRV in the cohort sample also are
representative of the distributions in the full cohort, thus
justifying the estimates of relative risks.
The use of certain medication was considered as a possible
confounding factor, because many drugs affect autonomic
nervous system function. The analyses for subjects without
chronic diseases (subjects who used antihypertensive,
glucose-lowering, or other cardioactive medication were
excluded) showed similar results. When the analyses were
restricted to persons not using any medication, the associa-
tions did not change.
Two-minute rhythm strips were used for the determination of
HRV. It is known from 24-hour Holter recordings that HRV
changes during the day.1 However, short-term HRV measure-
ments during the daytime are correlated with 24-hour HRV
measures, and in patients with myocardial infarction, such
short-term HRV measurements predict future mortality rates.3
Heart rate was correlated with measures of HRV and
associated with mortality risk and therefore may be consid-
ered a possible confounding variable. Because both heart rate
and HRV reflect autonomic function, the inclusion of both
parameters was regarded as an overadjustment. When the
coefficient of variation was used, SDNN divided by mean
R-R interval, the age-, sex-, race-, and field center–adjusted
relative risks of the lowest versus the intermediate tertile were
1.82 (1.07 to 3.09) for CVD mortality and 1.45 (1.04 to 2.03)
for CHD incidence.
Previous Studies
Previous work in the ARIC study, with spectral analysis of
heart rate, has shown low HRV to predict incident CHD.7 The
results of the present study confirmed this association over a
TABLE 1. Baseline Characteristics in Tertiles of 2-Minute SDNN in the Random Sample
Low (,23.9 ms) Intermediate (23.9–35.4 ms) High ($35.4 ms) P (ANOVA)
n 280 281 295
Age, y 55.1 53.7 52.0 0.0001
Sex, % men 44 40 51 0.0243
Race, % black 28 29 27 0.208
Heart rate, bpm 74 67 63 0.0001
Current smoking, % 30 29 26 0.461
Smoking, cigarette-y 341 290 247 0.050
Body mass index, kg/m2 28.9 28.0 27.3 0.002
Waist/hip ratio 0.947 0.931 0.923 0.0001
Insulin, pmol/L*† 77.2 66.7 60.4 0.001
Triglycerides, mmol/L† 1.32 1.17 1.15 0.002
HDL cholesterol, mmol/L 1.29 1.34 1.40 0.009
LDL cholesterol, mmol/L 3.63 3.64 3.47 0.117
Systolic blood pressure, mm Hg 125 122 121 0.011
Carotid intima-media thickness, mm 0.75 0.74 0.72 0.038
Hypertension, % 36 34 28 0.076
Diabetes, % 13 9 6 0.012
Values are least-squares adjusted mean values, adjusted for age, sex, race, and field center. Age, sex, race, and field center were
adjusted for the other 3.
*Subjects with diabetes and subjects who did not fast 12 hours before blood sampling were excluded for this analysis.
†Because triglycerides and insulin were not normally distributed, log transformation was performed, and the antilog of the mean
is presented.
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longer follow-up period with the use of different methodol-
ogy (time domain) and a different subset of the ARIC cohort.
The consistency of these results strengthens confidence that
low HRV is an important predictor of CHD events. In
addition, Tsuji et al6 reported low HRV, as determined in
2-hour ambulatory ECG recordings, to be a risk indicator for
incident CHD in the elderly participants of the original
Framingham Heart Study, combined with the younger sub-
jects from the Framingham Offspring Study. In the elderly
cohort, low HRV was a strong predictor of death,4 but
because of the limited number of cases, the relation with
specific causes of death could not be analyzed. In the Zutphen
Study,5 a prospective study in middle-aged and elderly Dutch
men, HRV was determined from 15- to 30-second recordings.
A strong association between low HRV and death from all
causes, including cancer, was observed. The results of the
present study are in line with these findings. Furthermore, we
were able to show that the predictive value of HRV for death
cannot be attributed to known underlying disease. The higher
risk of death in the high-HRV group observed in the present
study was also reported in the Zutphen Study.
Mechanisms
Heart rate and HRV are influenced by the autonomic nervous
system. The rMSSD, SDSD, and pNN50 mostly reflect fast
breathing–related beat-to-beat changes and are measures of
TABLE 2. Relative Rates (95% CIs) of Death From Several Causes and CHD Incidence in Tertiles of HRV and Heart Rate
in a 2-Minute Rhythm Strip
Measure Tertile* All-Cause Death CVD Mortality Cancer Mortality‡ CHD Incidence
No. of events 443 140 173 395
SDNN 1 †1.51 (1.08–2.18) 2.10 (1.21–3.64) 1.20 (0.79–1.82) 1.18 (0.84–1.64)
1.50 (1.02–2.21) 1.98 (1.06–3.70) 1.18 (0.72–1.92) 1.09 (0.73–1.64)
2 1 1 1 1
3 1.03 (0.72–1.48) 1.20 (0.66–2.18) 1.08 (0.70–1.70) 0.72 (0.51–1.03)
1.23 (0.80–1.89) 1.61 (0.78–3.34) 1.37 (0.83–2.28) 0.92 (0.58–1.91)
rMSSD 1 1.73 (1.22–2.44) 2.60 (1.48–4.59) 1.47 (0.96–2.25) 1.36 (0.97–1.92)
1.95 (1.30–2.93) 2.80 (1.36–5.75) 1.70 (1.02–2.84) 1.49 (0.99–2.25)
2 1 1 1 1
3 1.09 (0.76–1.56) 1.06 (0.59–1.93) 1.17 (0.75–1.83) 0.98 (0.69–1.40)
1.13 (0.72–1.77) 0.97 (0.44–2.16) 1.49 (0.88–2.52) 1.10 (0.70–1.71)
SDSD 1 1.90 (1.33–2.69) 2.83 (1.59–5.03) 1.56 (1.00–2.42) 1.43 (1.01–2.03)
1.97 (1.30–2.97) 3.18 (1.47–6.90) 1.90 (1.13–3.21) 1.42 (0.92–2.17)
2 1 1 1 1
3 1.37 (0.96–1.96) 1.52 (0.84–2.74) 1.35 (0.87–2.11) 1.04 (0.73–1.48)
1.41 (0.91–2.20) 1.43 (0.66–3.11) 1.90 (1.13–3.20) 1.16 (0.74–1.79)
pNN50 1 2.16 (1.53–3.02) 2.87 (1.59–5.03) 1.95 (1.27–2.92) 1.61 (1.15–2.26)
2.35 (1.57–3.50) 3.44 (1.69–7.02) 2.48 (1.48–4.15) 1.69 (1.12–2.55)
2 1 1 1 1
3 1.40 (0.97–2.02) 1.33 (0.73–2.44) 1.53 (0.97–2.41) 1.16 (0.81–1.65)
1.46 (0.92–2.32) 1.24 (0.55–2.79) 2.10 (1.23–3.81) 1.29 (0.82–2.03)
Heart rate 1 1 1 1 1
2 1.26 (0.88–1.80) 1.35 (0.77–2.38) 1.22 (0.79–1.90) 1.25 (0.88–1.77)
1.02 (0.66–1.58) 1.06 (0.52–2.17) 1.04 (0.62–1.76) 1.03 (0.66–1.61)
3 1.82 (1.29–2.57) 1.93 (1.13–3.30) 1.61 (1.05–2.48) 1.35 (0.95–1.91)
1.71 (1.14–2.55) 1.84 (0.94–3.59) 1.39 (0.86–2.25) 1.09 (0.72–1.66)
*Categories are based on the tertile cut points of the distribution of subjects in the random sample. The cut points were 23.9 and 35.4 ms for SDNN,
14.7 and 22.3 ms for rMSSD, 11.3 and 16.4 ms for SDSD, 0.8% and 5.9% for pNN50, and 63 and 72 bpm for heart rate.
†Relative incidence rates were calculated by Poisson regression for the case-cohort design. Rates are relative to the intermediate HRV categories
and the low heart rate category (indicated by relative rate51). Two rows of relative rates are given. The first row shows the relative rates adjusted
for age, sex, race, and field center. The second row shows the relative rates adjusted for age, sex, race, field center, current smoking, cigarette-years,
triglycerides, HDL cholesterol, diabetes, hypertension, body mass index, waist/hip ratio, and carotid intima-media thickness.
‡For cancer mortality, the multivariable model adjusts for age, sex, race, field center, current smoking, and cigarette-years.
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parasympathetic involvement in circulatory control.2 The
SDNN in a 2-minute recording contains both Mayer waves
(10-second fluctuations) and fast fluctuations in heart rate and
reflects sympathetic as well as parasympathetic involvement.2
In general, with sympathetic predominance, HRV is re-
duced, and the risk of (fatal) arrhythmias is elevated,1 which
may explain mortality risk in patients with myocardial infarc-
tion who have low HRV.3 However, this cannot account for
TABLE 3. HRV and Heart Rate in a 2-Minute Rhythm Strip in Relation to Death From Several Causes and CHD Incidence
According to Health Status
Measure Tertile* All-Cause Death CVD Mortality Cancer Mortality CHD Incidence
Subjects without hypertension, diabetes,
symptomatic heart disease, or cancer (n5532)
SDNN 1 †1.69 (1.11–2.57) 1.77 (0.99–3.14) 1.34 (0.77–2.34) 1.25 (0.83–1.88)
2 1 1 1 1
3 1.47 (0.80–2.40) 1.30 (0.59–2.43) 1.64 (0.89–3.00) 0.94 (0.58–1.52)
rMSSD 1 1.58 (1.02–2.43) 2.29 (1.24–4.25) 1.13 (0.64–1.98) 1.62 (1.05–2.51)
2 1 1 1 1
3 1.00 (0.62–1.61) 1.08 (0.48–2.12) 1.02 (0.56–1.86) 1.14 (0.71–1.84)
SDSD 1 1.91 (1.19–3.06) 3.04 (1.51–6.11) 1.31 (0.72–2.36) 1.44 (0.90–2.32)
2 1 1 1 1
3 1.29 (0.79–2.08) 1.69 (0.84–3.38) 1.12 (0.61–2.05) 0.96 (0.59–1.57)
pNN50 1 2.08 (1.34–3.23) 2.80 (1.52–5.14) 1.77 (1.00–3.13) 2.30 (1.46–3.65)
2 1 1 1 1
3 1.30 (0.81–2.07) 1.28 (0.66–2.47) 1.47 (0.80–2.70) 1.52 (0.94–2.47)
Heart rate 1 1 1 1 1
2 1.02 (0.63–1.64) 1.13 (0.30–1.73) 0.89 (0.48–1.62) 1.16 (0.73–1.84)
3 2.19 (1.38–3.47) 2.35 (1.27–4.36) 1.86 (1.05–2.31) 1.61 (1.02–2.56)
Subjects with hypertension, diabetes,
symptomatic heart disease, or cancer (n5321)
SDNN 1 †1.36 (0.87–2.14) 2.38 (0.95–5.93) 1.07 (0.61–1.87) 0.92 (0.56–1.49)
2 1 1 1 1
3 0.97 (0.47–1.22) 0.80 (0.29–2.22) 0.86 (0.48–1.53) 0.59 (0.36–0.96)
rMSSD 1 1.98 (1.23–3.30) 3.27 (1.23–8.68) 1.58 (0.89–2.81) 1.09 (0.67–1.77)
2 1 1 1 1
3 1.37 (0.85–2.20) 1.09 (0.39–3.06) 1.28 (0.71–2.31) 0.96 (0.59–1.57)
SDSD 1 2.01 (1.25–3.23) 2.29 (0.97–5.42) 1.63 (0.90–2.95) 1.29 (0.79–2.10)
2 1 1 1 1
3 1.60 (0.99–2.59) 0.82 (0.30–2.27) 1.67 (0.93–2.99) 1.17 (0.72–1.90)
pNN50 1 2.75 (1.70–2.37) 3.81 (1.46–9.96) 2.07 (1.15–3.72) 1.08 (0.67–1.73)
2 1 1 1 1
3 1.99 (1.19–3.22) 1.56 (0.52–4.69) 1.82 (0.98–3.38) 1.01 (0.62–1.64)
Heart rate 1 1 1 1 1
2 1.48 (0.92–2.37) 1.40 (0.59–3.30) 1.58 (0.89–2.78) 1.35 (0.84–2.19)
3 1.41 (0.88–2.35) 1.38 (0.57–3.33) 1.13 (0.62–2.06) 0.90 (0.55–1.48)
*Categories were based on the tertile cut points of the distribution of subjects in the random sample. The cut points were 23.9 and 35.4 ms for
SDNN, 14.7 and 22.3 ms for rMSSD, 11.3 and 16.4 ms for SDSD, 0.8% and 5.9% for pNN50, and 63 and 72 bpm for heart rate.
†Relative incidence rates were calculated by Poisson regression for the case-cohort design. Rates are relative to the intermediate HRV categories
and the low heart rate category (indicated by relative rate51). Relative rates are adjusted for age, sex, race, and field center.
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the observed adverse cardiovascular risk profile and greater
incidence of nonfatal CHD in subjects with low HRV in the
present study, so other explanations are needed.
Many other factors affect autonomic nervous system
function and, thus, HRV. HRV decreases with age,7 high
insulin level,16 reduced baroreflex sensitivity,17 physical
inactivity,18 rapid and shallow breathing,19 smoking,20
depression,21 atherosclerosis,9 obstructive sleep apnea,22
and diabetic autonomic neuropathy.1 Autonomic nervous
system function affects all organ systems, including the
immune system. Direct effects of sympathetic activity on
the function, number, and subset distribution of circulating
lymphocytes have been described.23,24 All of these mech-
anisms may have contributed to the observed associations.
However, our measures of age, insulin, smoking, hyper-
tension, physical activity, atherosclerosis, diabetes, and
cancer did not explain these relationships. In addition, the
association was present in subjects without known disease.
This suggests that low HRV precedes manifest disease.
Possibly, sympathetic predominance, as reflected in low
HRV and high heart rate, may be indicative of less
favorable general health, with HRV being a more sensitive
indicator than heart rate.
In conclusion, in a population-based study of middle-aged
men and women, high heart rate and, especially, low HRV
were predictive of increased mortality rates. For HRV, this
relation could not be attributed to cardiovascular risk factors
or to underlying disease. It may be hypothesized that low
HRV is an indicator of poor general health.
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